COP Research Update — August 28, 2026 (Updated)
Updated Thesis
ConocoPhillips is a large, diversified global exploration and production company with 2.248 MMBOED of Q2 2026 production, 7.637 BBOE of year-end-2025 proved reserves, leading Lower-48 scale and growing LNG optionality. Business quality is medium rather than high because its scale, Delaware Basin productivity gains, Marathon integration synergies above $1 billion run-rate and disciplined shareholder-return framework are offset by direct commodity-price exposure, a 6% reported production decline in Q2 and elevated project execution risk. Sales increased 36.8% and earnings increased 99.4% year over year in the most recent quarter, although the revenue increase was principally price-led, with higher crude and bitumen prices contributing $3.730 billion while lower volumes reduced revenue by $409 million.
The investment grade as of this refresh is B — solid business quality. B-tier business, A-tier blended-fair-value valuation, with 42.6% upside to $194.68 fair value but meaningful commodity, production and execution risk.
Grade Change
In this research cycle, the investment grade for ConocoPhillips moved from C to B. B-tier business, A-tier blended-fair-value valuation, with 42.6% upside to $194.68 fair value but meaningful commodity, production and execution risk.
Key Metrics at a Glance
- Revenue growth: +36.8% year over year
- Net margin: 14.7%
- Fair value upside: +42.6% to our estimate of $195
Current price: $136.53
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. ConocoPhillips remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full COP research →](/stocks/COP)